Company Monitoring Page for Alnylam

latest headlines for company on cafepharma

Alnylam and Regeneron report updated positive Phase I results of Alzheimer’s drug
Clinical Trials Arena
Mon, 07/17/23 - 08:41 am
Tags:
Alnylam, clinical trials, ALN-APP, Alzheimer's disease
5 FDA decisions to watch in the third quarter
BioPharma Dive
Mon, 06/26/23 - 10:04 am
Tags:
FDA, SAGE Therapeutics, Biogen, zuranolone, Eisai, Leqembi, Sanofi, AstraZeneca, nirsevimab, Iveric Bio, Zimura, Alnylam, Onpattro
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Fierce Pharma
Tue, 05/16/23 - 10:38 pm
Tags:
Moderna Therapeutics, Alnylam, MRNA, vaccines, legals
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Fri, 04/28/23 - 10:08 am
Tags:
Alnylam, Regeneron, clinical trials, Alzheimer's disease, ALN-APP
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Mon, 04/24/23 - 10:26 am
Tags:
Ionis Pharmaceuticals, AstraZeneca, eplontersen, Alnylam, ATTR
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
Mon, 03/27/23 - 10:22 am
Tags:
AstraZeneca, Ionis Pharmaceuticals, aplontersen, Alnylam, Onpattro, clinical trials, ATTRv-PN
JPM Day 1: Highlights
BioSpace
Mon, 01/9/23 - 11:01 pm
Tags:
JPMHC 2023, Sarepta Therapeutics, Biomarin, Alnylam, JNJ, Arrowhead Pharmaceuticals, Novartis, Bristol Myers Squibb
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
Tags:
clinical trials, Alzheimer's disease, obesity, Huntington's disease, M&A, AstraZeneca, Daiichi Sankyo, Nimbus Therapeutics, Takeda, Eli Lilly, Sanofi, Regeneron, Moderna Therapeutics, Gilead Sciences, Pfizer, Roivant, Alnylam, uniQure
Insmed, Alnylam and others make Science's list of top 20 biopharma employers
Endpoints
Sun, 11/6/22 - 01:32 pm
Tags:
employers, Inbsmed, Alnylam, Regeneron, Incyte
Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA
BioSpace
Mon, 10/31/22 - 04:17 pm
Tags:
Sanofi, Alnylam, earnings, Inflation Reduction Act, legislation, drug pricing
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Fri, 10/28/22 - 10:25 am
Tags:
Alnylam, RNAi, vutrisiran, Stargardt disease, Inflation Reduction Act, drug pricing
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
Tags:
biopharma stocks, AbbVie, Alnylam, AstraZeneca, Biogen, CRISPR Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, GSK, Intellia Therapeutics, Regeneron, Roche, Sanofi, Sarepta Therapeutics
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
Tags:
FDA, Alnylam, Cytokinetics, Eli Lilly, Owlet, Boston Cell Standards, Kiromic Biopharma, Entera Bio, Transcenta Holdings, Kira Pharmaceuticals, Kite Pharma, Poxel, Seneca Therapeutics
FDA approves label expansion of Alnylam’s Oxlumo for PH1
Pharmaceutical Business Review
Fri, 10/7/22 - 10:38 am
Tags:
Alnylam, FDAA, Oxlumo, advanced primary hyperoxaluria, PH1
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Mon, 10/3/22 - 11:41 pm
Tags:
Alnylam, Onpattro, Pfizer, ATTR-CM
Alnylam details anticipated results from heart disease drug trial
BioPharma Dive
Thu, 09/8/22 - 10:47 am
Tags:
Alnylam, clinical trials, Onpattro, transthyretin amyloidosis with cardiomyopathy
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
Wed, 09/7/22 - 10:18 am
Tags:
AstraZeneca, Ionis Pharmaceuticals, Alnylam, antisense, ATTRv-PN, aplontersen
Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas
Fierce Biotech
Tue, 08/30/22 - 11:48 am
Tags:
Alnylam, Regeneron, Calliditas, immunoglobin A nephropathy, clinical trials
Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer
MedCity News
Thu, 08/4/22 - 11:09 am
Tags:
Alnylam, Pfizer, Onpattro, hATTR
Alnylam reveals longer wait for anticipated drug trial results
BioPharma Dive
Thu, 07/28/22 - 12:25 pm
Tags:
Alnylam, earnings, clinical trials, Onpattro

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.